Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

The war has bugger all to do with it IMO. That -along with inflation, poor pharma fundamentals was a comfortable crutch to excuse major structural issues befelling the company. We are in the midst of a serious economic downturn that is not going to go away quickly & the company needs to push its way through that to succeed. Something has to change (what -I don’t know) as we can’t keep doing the same old same old. Whacking the CEO is the easy knee jerk reaction. As a suggestion those with concerns may want to reach out (as suggested on every release) to Gennadi Koutchin- after all he is freely listed to receive investor enquires. That said I reckon he is part of the problem not the solution. A very unilluminating update. I don’t have problems with the $$ but the vibe is poor & that can be addressed with better external advice.